U.S. FDA Establishes Nicotine Steering Committee
According to translated industry reports, the U.S. Food and Drug Administration (FDA) has announced that it is forming a Nicotine Steering Committee to help develop and implement nicotine policy and regulation. The goal is to support the agency’s comprehe
According to a translated report from Tobacco Online citing Tobacco Business Communications, the U.S. Food and Drug Administration (FDA) recently said it is forming a Nicotine Steering Committee to help develop and implement nicotine policy and regulation. It is understood that the purpose of implementing this policy is to support the comprehensive new tobacco regulatory plan announced by the agency in July, addressing what the FDA called “the public health crisis of addiction to tobacco products in this country.”
Committee members include senior leaders from the Center for Tobacco Products (CTP), the Center for Drug Evaluation and Research, and the Office of the Commissioner, with a focus on studying nicotine replacement therapies (NRTs) that help people quit smoking. In a press release, the CTP noted: “The committee will review the evolving science that supports the agency’s evaluation of NRTs, including the types of safety and effectiveness studies required by the FDA and how these products should be used and labeled. The committee’s first action will be to hold a public hearing to obtain feedback on the public health, scientific, regulatory, and legal considerations related to NRT products and their use in smoking cessation.”
The hearing is scheduled for January 26 at the White Oak Campus in Silver Spring, Maryland, USA. Requests to register and attend the hearing had to be completed by January 2. However, electronic or written comments may be submitted until February 15, after the public hearing.
